Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | The prognostic role of t(11;14) in patients with newly diagnosed AL amyloidosis

Despina Fotiou • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Bortezomib Venetoclax

Despina Fotiou, MD, PhD, University of Athens, Athens, Greece, discusses the prognostic impact of t(11;14) in patients with newly diagnosed AL amyloidosis. Dr Fotiou first explains how t(11;14) may decrease patient response to treatment with bortezomib, and then highlights the potential role of BCL2 inhibitors in these patients. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

More from Despina Fotiou

2:00
Time to next treatment as a prognostic marker in patients with AL amyloidosis
Despina Fotiou • 6 Sep 2022
1:58
Improving diagnosis in AL amyloidosis using surrogate organ tissues for biopsies
Despina Fotiou • 6 Sep 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals